Format

Send to

Choose Destination
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.

Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.

Author information

1
Institute for Microbiology, Immunology and Laboratory Medicine, Helios Klinikum Emil von Behring, Berlin.
2
Synlab Gauting, synlab MVZ Humane Genetik.
3
IML red GmbH, Tuberculosis Supranational Reference Laboratory, Gauting.
4
Molecular and Experimental Mycobacteriology, Research Center Borstel.
5
German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel.
6
Department of Pneumology, Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin.
7
National Reference Laboratory for Mycobacteria, Research Center Borstel, Borstel, Germany.
8
Clinical Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Abstract

Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

KEYWORDS:

XDR-tuberculosis; bedaquiline resistance; delamanid resistance

PMID:
30933266
DOI:
10.1093/cid/ciz074

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center